| |
 |
| |
News Media
Center |
|
|
|
|
| |
Sword
Diagnostics Inc. Technology featured in IVD Technology’s DX
Directions
Chicago, IL - Jul 13, 2010 –
Sword Diagnostics is pleased to announce that it’s technology
was featured in the Summer issue of DX Directions from IVD Technology
Magazine. The peer-reviewed article features an in-depth description
of the technology as well as comparative data with other technologies
in various types of assays.
Click
here to download PDF
Title: Developing a Raman detection system for Immunoassays
Authors: Samar Kundu, Neal Siegel, and Charles Ginsburg
DX Directions, Summer, 2010, p 5-10
“We are pleased with the positive reception our technology
has received from the market. The key opinion leaders have found
it particularly useful for highly sensitive ELISAs,” said
Dave Dingott, founder and CEO of Sword Diagnostics. “The Raman
plate reader allows current ELISA users to continue using their
96-well format, making conversion to our technology extremely simple
and cost effective.”
About
Sword Diagnostics
Sword Diagnostic’s mission is to improve existing medical
diagnostic tests by providing additional sensitivity to each currently
available antibody-based test as well as allowing clinicians to
monitor new markers that are not detectable with current technology.
This will allow earlier and more accurate diagnosis of diseases
such as cancer, cardiovascular disorders, and Alzheimer’s
disease. Better diagnosis results in simpler treatments with more
positive outcomes for patients and less costs.
Sword markets its technology for biomarker measurement for pharmaceutical
drug discovery and academic life science researchers and will partner
to develop clinical diagnostics assays.
The technical solution is an immunoassay detection system that uses
Raman spectroscopy and a proprietary chemistry. The system extends
the sensitivity over current detection technologies while being
easily incorporated into assays that use a peroxidase-based detection
system.
Contact:
Dave Dingott, President
Tel: 708-563-9166 x221
ddingott@sworddiagnostics.com
www.sworddiagnostics.com |
|
|
|
|
|
Life
Sciences Company Sword Diagnostics Moves Operations to Chicago
Chicago, IL (Vocus/PRWEB ) April 27, 2010 — Sword Diagnostics,
Inc., committed to improving healthcare through the use of innovative
detection technology, today announced the relocation of its corporate
headquarters and research facilities to accommodate planned growth.
Double the size of its current space in the suburbs, Sword’s
new location at University Technology Park at IIT (UTP) in Chicago
marks its shift from start-up venture to growth-stage commercial
entity.
Sword launched its proprietary biological detection system in January
2010, closely following the issuance of the company’s core
patent. Developed for ultra-sensitive immunoassays, the technology
allows greater sensitivity and improved accuracy in disease marker
testing, without increasing cost or complexity. Such performance
enhancements accelerate gains in basic and clinical research, drug
discovery, and clinical diagnostics development, leading to advancements
in disease detection.
"This is an important milestone
for our company,” said Sword Diagnostics President Dave Dingott.
"Our new facility at UTP not only offers more space, better
working conditions for the team and access to university resources,
but moving from suburban Chicago into the city also improves Sword’s
ability to attract top talent with its metropolitan location –
all key factors in our continued growth.
"The UTP
lease allows us to expand into adjacent suites as the need arises
without prematurely incurring costs. Wexford’s flexibility
and willingness to partner with its tenants is critically important
to high growth-stage companies like Sword Diagnostics.”
"Sword is a great example of the type of life science
company that the Technology Business Center within UTP is designed
for and dedicated to supporting,” said Catherine E. Vorwald,
director of business development for Wexford
Science + Technology, LLC. "UTP and IIT are able to offer
Sword the resources, expertise, and environment it will need to
grow and expand for many years to come. We are proud to add Sword
to our growing roster of UTP tenants.”
Sword Diagnostics, Therapeutic Proteins, Chromatin, and Wrightwood
Technologies will be among the UTP tenants who will participate
in the Association of University Park’s (AURP) BioParks 2010
tour and reception at IIT on May 1. For more information on the
two-day program, visit www.aurp.net/bioparks2010.
About Sword Diagnostics
Sword Diagnostics is a life sciences company committed to improving
healthcare through the use of innovative detection technology. Selling
to research facilities in pharmaceutical companies, academia and
government, Sword helps its customers develop more sensitive biomarker
tests without increasing cost or complexity. Sword’s patented
biological detection technology accelerates the identification of
existing and emerging disease markers, making researchers’
dream of early disease detection a reality. For more information,
visit http://www.sworddiagnostics.com.
About University Technology Park
at IIT (UTP)
The University Technology Park at IIT (UTP) is home to more than
20 emerging technology-based companies and the Illinois Institute
of Technology’s Pritzker Institute for Biomedical Science
+ Engineering. Launched in 2006, UTP's mission is to move innovation
forward by providing quality flexible lab and office space for technology
companies at every stage of their growth, and by offering tenants
the resources of IIT and the community. The park's four-building
complex includes the Technology Business Center (TBC), a technology
incubator, a 19-story office tower, and the IIT Research Institute.
For more information, visit http://www.universitytechnologypark.com.
About Wexford Science & Technology,
LLC
Wexford Science & Technology, LLC (www.wexfordequities.com)
is a privately held real estate investment and development company
that delivers the real estate solution for science, technology,
and healthcare based organizations. Headquartered in Baltimore,
Wexford Science & Technology has projects in the contiguous
United States with the University of Maryland, Baltimore, The Science
Center (Philadelphia), Illinois Institute of Technology, Old Dominion
University, the Hershey Center for Applied Research (Hershey Trust)
, the University of Miami, and Wake Forest University.
For more information, contact:
Catherine E. Vorwald
Director, Business Development
Wexford Science + Technology, LLC
(443) 844-4172
Dave Dingott
President
Sword Diagnostics, Inc.
312-235-3661
info@sworddiagnostics.com
|
|
|
|
|
|
|
|
|
| |
Sword
Diagnostics Announces Availability of Proprietary Detection Technology
for Ultrasensitive Immunoassays
Chicago,
IL - Jan 14, 2010 – Sword Diagnostics announced today
the launch of its proprietary Raman detection system for ultrasensitive
immunoassays. The system provides researchers with greater sensitivity
which enables more accurate testing of low abundance markers. These
increases in performance could aid researchers in basic and clinical
science research, drug discovery, and clinical diagnostics development.
“We find the resolution at low concentrations to be an
exciting benefit in our ovarian cancer and infertility research,”
said Professor Judith Luborsky, Ph.D, Associate Dean for Research,
College of Health Sciences, Director, Laboratory for Ovarian Cancer
Research and Director, Rush Proteomics & Biomarkers Core Research
Facility at Rush University Medical Center. “The technology
was easily integrated into existing tests with minimal optimization
and provided excellent improvements. In fact, we have included Sword
technology in several grants we are currently applying for.”
“We are pleased with the positive reception our technology
has received from the market. The key opinion leaders have found
it particularly useful for highly sensitive ELISAs,” said
Dave Dingott, founder and CEO of Sword Diagnostics. “The Raman
plate reader allows current ELISA users to continue using their
96-well format, making conversion to our technology extremely simple
and cost effective.”
About
Sword Diagnostics
Sword Diagnostic’s mission is to improve existing immunoassays
by providing additional sensitivity to currently available antibody-based
test as well as allowing researchers to monitor new markers that
are not readily detectable with current technology. This may lead
to earlier and more accurate diagnosis of diseases such as cancer,
cardiovascular disorders, and Alzheimer’s disease. Better
diagnosis results in simpler treatments with more positive outcomes
for patients and less costs.
Sword markets its technology for biomarker measurement for pharmaceutical
drug discovery and academic life science researchers and will partner
to develop clinical diagnostics assays. The technical solution is
an immunoassay detection system that uses Raman spectroscopy and
a proprietary chemistry. The system extends the sensitivity over
current detection technologies while being easily incorporated into
assays that use a peroxidase-based detection system.
Contact:
Dave Dingott, President
Tel: 708-563-9166 x221
ddingott@sworddiagnostics.com
www.sworddiagnostics.com
|
|
|
|
|
|
|
|
|
| |
U.S.
Patent Office Issues Sword Diagnostics Patent for Highly Sensitive
Immunodetection Technology
Chicago,
IL - Dec 14, 2009 – Sword Diagnostics, Inc. is
pleased to announce that the United States Patent Office (USPTO)
has issued patent number 7,599,057 titled “ Method and Apparatus
for Detection of Biological Organisms using Raman Scattering”
to the company. The patent covers the core technology which focuses
on improved sensitivity and specificity.
“The issuance
of this patent supports the underlying strategy as we move forward
with our continued development and commercialization” said
Dave Dingott, CEO and President of Sword Diagnostics. “The
feedback from our immunoassay customers validates the high degree
of need in the market for a technology that delivers improved sensitivity
without compromising in cost or complexity of the test.”
About Sword Diagnostics
Sword Diagnostic’s mission is to improve existing medical
diagnostic tests by providing additional sensitivity to each currently
available antibody-based test as well as allowing clinicians to
monitor new markers that are not detectable with current technology.
This will allow earlier and more accurate diagnosis of diseases
such as cancer, cardiovascular disorders, and Alzheimer’s
disease. Better diagnosis results in simpler treatments with more
positive outcomes for patients and less costs.
Sword markets its technology for biomarker measurement for pharmaceutical
drug discovery and academic life science researchers and will partner
to develop clinical diagnostics assays.
The technical solution is an immunoassay detection system that uses
Raman spectroscopy and a proprietary chemistry. The system extends
the sensitivity over current detection technologies while being
easily incorporated into assays that use a peroxidase-based detection
system.
Contact:
Dave Dingott, President
Tel: 708-563-9166 x221
ddingott@sworddiagnostics.com
www.sworddiagnostics.com |
|
|
|
|
|
|
|
